首页> 中文期刊> 《中国药业》 >重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合心理干预治疗类风湿性关节炎的疗效及经济学评价

重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合心理干预治疗类风湿性关节炎的疗效及经济学评价

         

摘要

Objective To investigate the effect of human recombinant type Ⅱtumor necrosis factor receptor antibody fusion protein com-bined with psychological intervention for treating rheumatoid arthritis and its compliance. Methods 70 patients with rheumatoid arthritis were admitted to the hospital from March 2014 to March 2015 were randomly divided into the control group and the observation group,35 cases in each group. The control group was given human recombinant type Ⅱtumor necrosis factor receptor antibody fusion protein,on this basis,the observation group was added psychological nursing intervention. The clinical efficacy of the two groups was compared,and the compliance of the patients with human recombinant type Ⅱtumor necrosis factor receptor antibody fusion protein was recorded,the cost of treatment,long-term profit and loss cost were recorded,and the adverse reactions were observed in the treatment. Results The total effec-tive rate of the observation group was 85. 71%,which had no significantly difference with 82. 86% of the control group( P > 0. 05). The treatment compliance of the observation group was significantly higher than those of the control group ( P 0. 05). Conclusion Psychological intervention can not improve the treatment of patients with rheumatoid arthritis in the application of human recombinant type Ⅱtumor necrosis factor receptor antibody fusion protein,but it can improve the treatment compliance,reduce the cost of treatment and long-term profit and loss cost,which is worthy of clinical promotion.%目的:探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合心理干预治疗类风湿性关节炎患者的疗效及依从性。方法选择医院2014年3月至2015年3月收治的类风湿性关节炎患者70例,随机分为对照组和观察组,各35例。对照组患者给予重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗,观察组患者在此基础上同时进行心理护理干预。比较两组患者的临床疗效,记录患者使用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白的依从性,统计患者的治疗费用、长期损益,观察治疗过程中不良反应的发生情况。结果观察组总有效率为85.71%,对照组总有效率为82.86%,两组差异无统计学意义( P>0.05)。观察组治疗依从性5项得分均显著高于对照组( P 0.05)。结论心理干预虽不能提高重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿性关节炎患者的有效率,但能提高患者的治疗依从性,降低患者的治疗费用及长期损益,值得临床推广。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号